Nicox: Financial report for the first half of 2026

Nicox unveiled its financial results for the first half of 2026, showing a notable increase in revenue to 3.5 million euros, compared to 1.5 million euros for the same period in 2025. The net loss was significantly reduced to 0.5 million euros, compared to 8.9 million euros in the first half of 2025.

The company has €8.4 million in cash as of August 31, 2026, ensuring financial visibility for more than 18 months. The development of the NCX 470, which is progressing towards commercialization in the United States and China, is on track thanks to the support of partners.

Niox continues to evaluate new ophthalmology projects. Reductions in operating expenses and cost control initiatives have contributed to the improved financial situation. Furthermore, the company's debt stood at €2.9 million as of June 30, 2026, primarily in the form of convertible bonds.